Spruce Biosciences Reports Q1 2025 Results and Updates

Spruce Biosciences, Inc. ( (SPRB) ) has released its Q1 earnings. Here is a breakdown of the information Spruce Biosciences, Inc. presented to its investors.

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for neurological disorders with significant unmet medical needs.

In its first quarter 2025 financial report, Spruce Biosciences highlighted its acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for treating Sanfilippo Syndrome Type B (MPS IIIB) and announced plans to submit a Biologics License Application (BLA) to the U.S. FDA by the first half of 2026.

Key financial metrics revealed that Spruce Biosciences ended the first quarter of 2025 with $25.6 million in cash and cash equivalents, which is expected to sustain operations through the end of the year. The company’s R&D expenses slightly increased to $10.8 million, while G&A expenses decreased to $3.7 million. The net loss for the quarter was reported at $14.0 million, up from $11.6 million in the same period last year.

Strategically, Spruce Biosciences has entered into a license agreement with HMNC Holding GmbH to conduct a Phase 2 study on tildacerfont for treating major depressive disorder (MDD), with results expected in the first half of 2026. The company is also focused on initiating a confirmatory study for TA-ERT, aiming for accelerated approval and expanded access programs.

Looking forward, Spruce Biosciences remains committed to advancing its pipeline and pursuing regulatory approvals, with a focus on addressing serious diseases with significant unmet medical needs.